Calixar provides a comprehensive range of services focused exclusively on membrane proteins (which account for over 70 per cent of therapeutic targets), including: identification, production, extraction, purification, stabilization and crystallization. Its patented technology, which has already been validated on a score of targets (including GPCR receptors, ionic channels, transporters and viral proteins), can isolate and purify any type of membrane protein in its complete native form, which remains stable in solution. The company’s services are aimed at private and public research establishments interested in the development of antibodies, especially those for therapeutic applications, drug discovery (screening and drug design) and vaccines.